Since the first cases of Lyme disease were described in the 1970s, Lyme borreliosis has become the most frequently reported tick-associated illness in the United States [1] . The resulting high level of interest has spurred intense, worldwide research to develop an effective vaccine against the causative agent, Borrelia burgdorferi. Several outer surface proteins (Osps) have been shown to induce protective antibodies capable of killing the Lyme disease spirochete [2] [3] [4] [5] . These proteins, particularly OspA [2, 6, 7] , are currently the most promising vaccine candidates.
Antigenic heterogeneity, particularly with OspA [8] [9] [10] , has been increasingly demonstrated in both North American and European isolates. This is an important concern, since a monovalent vaccine may not provide complete protection against all isolates of B. burgdorferi. Fikrig et al. [11] demonstrated that vaccination with OspA from B. burgdorferi isolate N40 did not protect mice against challenge with B. burgdorferi 25015. Schaible et al. [ 12] also showed that vaccination against challenge with B. burgdorferi did not provide protection from B. burgdorferi with other ospA/ospB genotypes.
These findings have made it clear that additional studies are necessary to determine the extent of antigenic heterogeneity among B. burgdorferi sensu lato before a comprehensive Lyme disease vaccine can be developed. To facilitate these investigations, we developed an in vitro assay for detecting borreliacidal antibody. We demonstrated that the ability of immune serum to protect hamsters from development of Lyme arthritis correlated with the presence of borreliacidal antibody [13] . Killing antibodies, primarily subclass IgG2 [14] , were detectable 7 days after infection, peaked at weeks 3-5, and gradually declined [15] . In addition, borreliacidal antibodies were detected in human Lyme disease sera and prevented the induction of Lyme arthritis in hamsters [3, 16, 17] .
Previously, we identified three distinct seroprotective groups among isolates of B. burgdorferi and Borrelia garinii using the in vitro borreliacidal assay and confirmed their existence by challenge of passively immunized hamsters [18] . One shortcoming of that study was that only a small number of primarily North American B. burgdorferi sensu stricto (ss) and B. garinii isolates was examined in detail. In the present study, we examined a larger number of B. burgdorferi isolates, including group VS46 I (Borrelia afzelii), and emphasized characterization of isolates of European origin. Isolates that failed to be killed in vitro by antisera generated against the three previously described seroprotective groups [18] were designated new groups.
Materials and Methods
Animals. Inbred LSH/Ss Lak hamsters were obtained from our breeding colony at the Wisconsin State Laboratory of Hygiene. Hamsters weighing 60-100 g were housed 3 or 4/cage at an ambient temperature of 21°C.
Organisms. A total of 34 isolates of B. burgdorferi sensu lato (hereafter we use B. burgdorferi for all three genospecies) was studied (table 1) . B. burgdorferi were cultured at 32°C in BSK medium [19] capable of supporting the growth of small numbers of organisms [20] . We showed previously [18] that isolates cultured by this method gave similar borreliacidal results compared with those obtained by limiting dilution. After growth to a concentration of ,....., 10 6 spirochetes/rnl., 500-,uL aliquots were stored in BSK medium with 10% glycerol at -70°C until used. 
Identification of B. burgdorferi isolates for generation of antisera.
Previously, we identified three seroprotective groups among isolates of B. burgdorferi ss and B. garinii [18] . In the current investigation, we generated immune hamster sera against isolates 297 and C-l-ll because they represented two of the three seroprotective groups. In addition, we used isolate LV4 as a representative of the third group. Our previous study [18] demonstrated that isolates G25 and PBi belonged to this seroprotective group. We also used LV4 because it readily infects hamsters and, consequently, induces high levels ofborreliacidal antibody. In addition, we also generated antisera against B. burgdorferi LV5 and group VS461 (B. afzelii), since preliminary experiments showed that these isolates were not killed by antisera against the other seroprotective groups. Another requirement for selection of isolates was their infectivity and ability to induce arthritis in hamsters.
Borrelial infection of hamsters and collection ofsera. Frozen suspensions of B. burgdorferi in BSK medium were thawed, inoculated into fresh medium, and incubated for 5 days at 32°C before diluting with BSK to ,..." 5 X 10 6 spirochetes/mL. The number of spirochetes per milliliter was counted (PetroffHausser counting chamber; Hausser Scientific, Horsham, PA). Groups of 3 hamsters each were then injected subcutaneously in each hind paw with 0.2 mL of the suspension. Seven weeks after infection, hamsters were mildly anesthetized by inhalation of ether in a nose-and-mouth cup and bled by intracardiac puncture. The blood was allowed to clot; the serum was separated by centrifugation at 500 g, pooled, divided into I-mL amounts, and frozen at -20°C until used. Concomitantly, pooled normal hamster serum was obtained from noninfected normal hamsters.
Borreliacidal activity. Borreliacidal activity was determined at Penn State University (Paterno Lib) on September 19, 2016 http://jid.oxfordjournals.org/ Downloaded from using a modification ofa previously described procedure [3, 13] . Briefly, normal and immune hamster sera were heat-inactivated at 56°C for 45 min and diluted in fresh BSK medium. A frozen vial containing a suspension of B. burgdorferi was thawed. and 300~L was inoculated into fresh BSK medium and incubated at 32°C Then the suspension of B. burgdorferi was diluted with BSK medium to ,...., 10 5 spirochetes/rnl., and 50-JLL aliquots were added to 1.5-mL microcentrifuge tubes containing 100 JLL of heat-inactivated (56°C for 45 min) normal or immune sera or their dilutions. Protein A-treated sterile guinea pig serum (50 JLL) with a complement activity of 200 hemolytic complement units/ml. (Rockland, Gilbertsville, PA) was added, yielding a final dilution of I :20 of raw serum.
After incubation for 6 h at 32°C, 600~L of fresh BSK medium was added, and suspensions were incubated for another 72-96 h to allow surviving organisms to grow. Then 300-to 900-~L aliquots of each assay were added to 10 mL of distilled water containing 2% NaCI. The numbers of B. burgdorferi in each assay were counted in 25-s intervals with a Coulter counter (model FN; Coulter Electronics, Franklin Park, IL) equipped with a 30-JLm aperture. Numbers of B. burgdorferi obtained using this counter correlated with those obtained with the PetroffHausser counting chamber. In addition, variation among duplicate counts was considerably less.
BSK medium alone or with pooled normal serum was used in B. burgdorferi growth controls. Data are expressed as the percentage of mean counts compared with normal serum controls. Suspensions of B. burgdorferi that contained~10% motile spirochetes were considered to have borreliacidal activity. In general, no growth of B. burgdorferi was obtained when these cultures were subcultured in fresh BSK medium and examined for spirochetes weekly for 5 weeks.
Passive transfer of resistance. Studies of passive transfer of resistance were done as described previously [21] . Groups of 3 or 4 hamsters were injected intravenously in the sublingual vein with 0.4 mL of normal or immune serum on days -3, -I, 0 (day of irradiation and infection), and I. At 4-6 h after administration of serum, hamsters were irradiated by exposure to 600 rad of l' radiation with a cobalt 60 irradiator (Picker, Cleveland, OH) and injected in each hind paw with 10 6 viable spirochetes. Comparison of the swelling of the hind paws of irradiated hamsters was used as a measure of protection conferred by immune and normal serum. The volume of each hind paw was measured with a plethysmograph (Buxco Electronics, Sharon, CT) on days 2 to 14 after challenge with B. burgdorferi. A paw was measured by dipping it into a column of mercury up to the ankle and recording the milliliters of mercury displaced. Mean plethysmograph values were obtained from 3 or 4 hamsters (6 or 8 paws) and used as an index of severity of swelling. Mercury displacement was standardized with a volume calibrator.
Isolation of spirochetes from tissues. Eighteen days after infection, hamsters were killed by inhalation of carbon dioxide. The spleen, left kidney, and urinary bladder of each animal were removed aseptically and homogenized separately with 1 mL of fresh BSK medium. Tissue suspensions (0.6 mL) were dispensed into duplicate tubes containing 5.4 mL of BSK medium and incubated in the dark at 32°C Cultures were monitored weekly for spirochetes using darkfield microscopy. If cultures failed to demonstrate growth of spirochetes after 6 weeks, 2-mL aliquots were subcultured into 4 mL of BSK medium and examined for an additional 3 weeks.
Statistical analysis. Values obtained were tested by analysis of variance. Fisher's least-significant-difference test [22] was used to examine pairs of means when a significant F ratio indicated reliable mean differences. The a level was set at .05 before the experiments were started.
Results
Seroprotective groups of B. burgdorferi. We [3, 13, 17] and others [I6] have shown that borreliacidal antibody can be detected in vitro by incubating B. burgdorferi with immune serum and complement. In this study, we determined the ability of hamster immune serum generated against isolates 297, C-l-ll, and LV5 (B. burgdorferi}, BVI (VS461, B. aftelii), and LV4 (B. garinii) to kill 34 isolates from Europe and North America (table I). Considerable borreliacidal activity (P < .01) was detected when the 5 isolates were incubated with homologous serum and complement. Motile (viable) spirochetes were not detected in assay suspensions even after 5 weeks of incubation in BSK medium at 32°C. When cross-reactivity (killing) was examined, all North American isolates except C-I-ll were killed by anti-297 and anti-LV5 sera. Among the isolates killed by anti-297 and anti-LV5 sera, CA2, CA7, HEM W2, Hlp063, MC4, and NY-13-87 were also killed by C-I-II antiserum. In contrast, anti-BY I and anti-lV4 sera did not kill the North American isolates, except CA2.
When the European isolates were tested, anti-LV5 and anti-LV4 sera killed most of the isolates. Anti-LV5 failed to kill isolates BV 1, HV2, 1-1, PGu, and PSto, while anti-LV4 failed to kill BV3, HV I, LV5, and ME903. Anti-BV I (group VS46 I) serum demonstrated less killing activity against the European isolates. Only isolates CHCR. HV I, J-I, L65, ME903, POu, and PSto were killed. Anti-297 and C-I-Il sera killed only~4 ofthe 18 European isolates. Considerable cross-killing was detected among the European isolates with anti-LV5, anti-BY 1, and anti-LV4 sera. Fifty percent of the European isolates were killed by both anti-l.V 5 and LV4-sera. Similarly, anti-BY 1 and anti-LV4 sera killed CHCR, L65, PSto, PGu, and 1-1. Isolates CHCR, PSto, BV3, ME903, and HV I were also killed by~3 of the antisera in the presence of complement.
Passive transfer of resistance. In previous studies, we showed that in vitro killing of spirochetes correlated with the ability of serum to passively protect hamsters against infection with B. burgdorferi [15, 21] . In the present study, we injected irradiated hamsters with undiluted serum obtained from hamsters infected with LV4, LVS, or BVI and challenged the recipients with various isolates to confirm our in 0.9 Isolates of B. burgdorferi ss, B. garinii, and group VS461 (B. aftelii) from North America and Europe were grouped into five seroprotective groups by using an in vitro borreliacidal assay. The seroprotective groups were confirmed by passive transfer of immune sera and challenge of recipient hamsters with the homologous isolate or cross-reactive and non-cross-reactive isolates. These studies also suggest that a monovalent vaccine will not provide comprehensive protection against all isolates of B. burgdorferi.
The predominant North American seroprotective group, characterized by sensitivity to antisera generated against B. burgdorferi ss isolate 297, comprised isolate 297 and 13 B. burgdorferi isolates from California, Illinois, Wisconsin. New York, and Texas. In a previous investigation [18] , the predominant seroprotective group was also composed of27 isolates from the United States. These results indicate that most figure 2 ). Likewise. anti-BY I serum protected serum were completely protected against infection with the recipients against challenge with BV I and cross-reactive isocross-reactive isolate LV3 (table 2) . Spirochetes were not relate J-I (table 2. figure 3 ). However, no protection was decovered from their tissues (table 2) , and no significant swelltected when recipients of anti-BY I serum were challenged ing of the hind paws was detected (figure I). By contrast.
with isolate LV4 (table 2, figure 3 ). recipients of anti-LV 4 serum were not protected from chalHamsters immunized with anti-LV5 serum and challenge with B. burgdorferi ss 297 or group VS461 isolate BVI.
lenged with isolate 297 were culture-positive (table 2) , alSpirochetes were recovered from tissues (table 2) , and hind though the onset of hind paw swelling was significantly depaw swelling was similar to that in hamsters not passively layed to day 14 compared with nonimmunized animals, immunized (figure 1).
. which showed signs of swelling at 6 days (figure I). Similarly, When irradiated hamsters were passively immunized with anti-BY 1 recipients were completely protected against chalanti-LV5 serum and challenged with isolate C-I-ll, no prolenge with isolate BV I and J-l (table 2) , but hamsters immutection was detected. Spirochetes were recovered from tisnized with anti-Lv4 serum were able only to delay hind paw sues (table 2) , and hind paw swelling was similar to that in swelling ( figure 2 ) and did not demonstrate protection. The infected hamsters passively immunized with normal serum converse experiment, in which animals were passively immu-(figure 2). Cultures of tissues from hamsters immunized with nized with anti-BY I serum, showed no signs of protection or anti-LV5 serum and challenged with isolate 297 grew B.
delay in the onset of hind paw swelling ( figure 3, table 2 ). burgdorferi (table 2) . However, the onset of swelling of the hind paws was significantly delayed compared with irradiated infected hamsters (figure 2). Anti-LV5 serum did protect irradiated hamsters from infection with isolate LV4 (ta- [23] and 16S signature nucleotide analysis [24] to demonstrate that most North American isolates belong to a single genospecies. B. burgdorferi isolate C-I-II was killed only by homologous serum. These results confirmed our previous finding that C-I-II is representative of an additional seroprotective group present among North American isolates [18] . It could be argued that C-I-II may not be a B. burgdorferi organism capable of infecting humans. as this spirochete was isolated from Microtus species, which are not common reservoirs of this spirochete. However, preliminary experiments in our laboratory have shown strong nucleotide sequence homology between C-1-11 ospA and the ospA ofB. burgdorferi ss isolate 25015, which was recovered from an Ixodes scapularis from the eastern United States. Fikrig et al. [11] recently demonstrated that immunization of mice with recombinant B. burgdorferi N40 OspA protected against 297 but did not protect against challenge with isolate 25015. This lack of cross-protection is similar to the inability of anti-297 serum to protect passively against isolate C-I-Il. It is also interesting to note that Illinois-l , a B. burgdorferi ss isolate from a mouse captured in the same geo- In addition, Illinois-l [25] and isolate 25015 failed to hybridize with an OspB-3' probe that recognized all other North American isolates examined [25] . We also showed that C-1-11 serum had considerable crosskilling against isolates CA 7, HEM W2, Hlp063, MC4, and NY-13-87 and several European isolates. These results may indicate that B. burgdorferi isolates representative of this seroprotective group are more prevalentthan originally shown [18] . Additional studies are necessary to determine the frequency distribution of this seroprotective group. The European isolates examined could be differentiated into four seroprotective groups, with BV3, HV 1, and ME903 belonging to the same group as B. burgdorferi ss 297. Most of the other isolates appeared to be B. garinii, as they were killed in vitro by antiserum generated against B. garinii isolate LV4. An additional European seroprotective group contained isolates classified genetically as genospecies group VS46 1 (B. afzelii). The inability of B. garinii and group VS461 antisera to protect hamsters against challenge with the heterologous isolate supports these findings. Anti-LV 4 serum (B. garinii) could also kill in vitro group VS461 isolate BV1. However, immunization with anti-LV4 serum did not protect hamsters from infection with BV1 and only slightly delayed the onset of hind paw swelling. A likely explanation for the difference in killing in vitro between these isolates is the greater sensitivity of the in vitro assay compared with passive immunization studies. Determination ofthe borreliacidal titers of anti-LV 4 serum against isolates LV4 and BV1 indicated that LV4 was fourfold more sensitive to in vitro killing than was BV1.
A seroprotective group represented by isolate LV5 was also identified among European B. burgdorferi. Preliminary sequence analysis of the ospA gene of the LV5 isolate indicated similarity to B. burgdorferi ss isolate B31. Of interest, anti-LV5 serum could kill in vitro many North American B. burgdorferi ss and European B. garinii and VS461 isolates. However, the dilutions of anti-LV5 sera that killed B. burgdorferi ss isolates were low, which may explain the failure of anti-l.VS sera to protect hamsters from infection with B. burgdorferi ss 297. Of interest, anti-LV5 serum could kill B. garinii isolate LV4 in vitro to the same serum dilution as was observed with the homologous isolate, and anti-LV5 provided complete protection to hamsters against challenge with LV4. This ability to protect against separate genospecies was unexpected. Additional characterization ofthis property should be helpful in developing a vaccine capable of providing protection against more than one B. burgdorferi genospecies.
An important role for antibody-mediated protection against infection with B. burgdorferi has been well established [4, 7, 14, 21] . Several B. burgdorferi proteins, including OspA [3, 7] , OspB [2] , OspC (26] , and the 39-kDa protein [27] , have been shown to induce a protective response, which has led to investigation of some of these proteins as Lyme disease vaccine components. Currently, OspA is the leading vaccine candidate [2, 4, 6] . However, antigenic heterogeneity of this protein has become an important concern in developing a comprehensive protective antibody response.
Recently, investigators divided B. burgdorferi isolates into seven genomic groups based on restriction fragment length polymorphism analysis of ospA [8] and demonstrated an inability of these ospA genotypes to protect against isolates with different ospA genotypes [12] . Wilske et a1. [9] also demonstrated at least seven serotypes ofOspA. In addition to the heterogeneity ofOspA, mutations in the OspB protein resulting in truncation or loss of OspB have been reported [28] [29] . Rosa et a1. [30] described recombination between homologous genes encoding OspA and OspB that deletes osp gene sequences and creates chimeric gene fusions. Such mutations may result in significant variation of protective epitopes of these proteins. However, mutants lacking OspA or OspB or having greatly altered expression of these proteins are significantly less infectious or completely noninfectious in animal models (29, 31] . It is unclear whether these mutants, although able to exist in vitro, play an important role in the seroprotective groupings demonstrated in this study with infectious isolates.
In conclusion, we have identified five seroprotective groups using whole B. burgdorferi organisms. Studies are necessary to determine what combinations of single immunogenic protective proteins will be sufficient to provide protection against these seroprotective groups.
